The treatment of Wilson's disease with zinc. IV. Efficacy monitoring using urine and plasma copper.
Progress has been made in establishing the efficacy and safety of oral zinc as a maintenance therapy for Wilson's disease. It is important to develop simple, noninvasive monitoring methods to assure the adequacy of zinc therapy in individual patients. In this paper we report the use of 24-hr urine copper and plasma copper measurements to monitor efficacy of zinc maintenance therapy in 30 Wilson's disease patients. In examples of therapeutic inadequacy such as noncompliance, these values increase. With continued long-term adequate therapy, they remain stable or decrease. These two simple monitoring tools appear to be very useful in monitoring Wilson's disease patients receiving zinc therapy.
D002570:Ceruloplasmin / Q000032:analysis; D003300:Copper / Q000097:blood* / Q000652:urine; D005500:Follow-Up Studies; D006527:Hepatolenticular Degeneration / Q000097:blood / Q000188:drug therapy* / Q000652:urine; D066298:In Vitro Techniques; D010396:Penicillamine; D015032:Zinc / Q000627:therapeutic use* / Q000652:urine
D003300:Copper; D002570:Ceruloplasmin; D010396:Penicillamine; D015032:Zinc